Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT.

Muhammad A Abdul-GhaniCurtiss PuckettJohn AdamsAhmad KhattabGozde BaskoyEugenio CersosimoCurtis TriplittRalph A De Fronzo

Published in: Diabetes care (2020)

Triple therapy with agents that improve insulin sensitivity and β-cell function in patients with new-onset T2DM produces greater, more durable HbA1c reduction than agents that lower glucose levels without correcting the underlying metabolic defects.

Keyphrases

combination therapy
glycemic control
blood glucose
type diabetes
metabolic syndrome
adipose tissue
blood pressure
insulin resistance